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CHAPTER I: Platelet biology and E-Cigarette
Section 1.1. Platelet physiology and function
Cardiovascular disease annually accounts for 17 million deaths worldwide. It is the
number one cause of death in the world (1). According to the American Heart Association,
annually, one in every three deaths are caused from a heart disease, stroke and other
cardiovascular diseases in the United States alone (2). Cardiovascular disease is tightly
linked to platelets, as platelets play an important role in the development of thrombosis,
which is a form of and a risk factor for other types of cardiovascular diseases (3).
Platelets are tiny disk-shaped anucleate cell fragments that are created in the bone
marrow from megakaryocytes (4-6). Platelets primarily function as regulators of
hemostasis and thrombosis (7). Hemostasis is the spontaneous arrest of blood loss from
an injured blood vessel (3, 6). In contrast, thrombosis is the pathological process in which
an occlusive thrombus forms and blocks blood flow to vital organs (i.e. inappropriate
formation of clots) (3).
Section 1.1.1. Platelet clot formation
When injury to the blood vessel wall occurs, two adhesion receptors are responsible for
regulating initial platelet adhesion, namely glycoprotein Ib-IX-V which binds to von
Willebrand factor, and glycoprotein VI which binds to collagen (8-13). Subsequently, rapid
signal transduction causes platelets to activate. During this activation; spreading and
secretion occur while platelets also undergo a cytoskeletal change, thus, changing shape
(7). In addition, aggregation and adhesion is supported by inside-out activation of
integrins. The main platelet integrin that is activated during platelet aggregation is αIIbβ3
1

(also known as GPIIb/IIIa), which binds to fibrinogen to mediate platelet aggregation (12,
14, 15). Furthermore, when platelet activation occurs, platelet secretion is initiated
ultimately resulting in the release of different platelet agonists, such as, adenosine
diphosphate (ADP) from the platelets storage granules, as well as the synthesis of the
lipid thromboxane A2 (TXA2). These agonists will lead to activation of further platelets and
their recruitment, until a plug made of platelet aggregates finally forms at the injury site
(4, 7, 16). In addition, platelets are involved in the conversion of the clotting factor
prothrombin to thrombin. Thrombin will convert fibrinogen to fibrin. Fibrin will create a
mesh in and around the injury site, thus, completing the hemostatic process (4).

Figure 1.1. (A) Schematic representation of platelet clot formation. (B) Platelet role in
hemostasis and thrombosis (17).
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Section 1.1.2. Transmembrane receptors
Agonists receptors that belong to this family are expressed on the surface of the platelets.
These agonists include ADP and thrombin receptors which play an important role in
platelet aggregation and secretion. ADP is a weak agonist that is found in dense granules,
and is secreted from platelets upon activation (16). ADP receptors are separated into two
different G-Protein coupled receptors (GPCR), those being P2Y1 and P2Y12; both of which
engage a different signaling pathway, namely Gαq and Gi, respectively (9, 13, 16, 18, 19).
In contrast, thrombin is a strong agonist that is produced from the enzymatic cleavage of
prothrombin (20). Further, thrombin receptors are separated into two different GPCR’s (in
humans) which are identified as PAR-1 and PAR-4, and they each engage a different
signaling pathway: Gαq, Gαi, Gα12/13 and Gαq, Gα12/13, respectively (9, 13, 18).
Section 1.1.3. G-protein coupled receptors signaling
The GPCRs are composed of a single polypeptide that is folded into a double helix of
seven segments, which is transmembrane in nature, and they are coupled to
heterotrimeric guanine-nucleotide binding-proteins (G-proteins), composed of an α, β,
and γ subunits, belonging to the Gq, G12/13, and Gi families. Upon ligand binding, the
receptor allows an exchange of GDP for GTP in the α-subunit. The exposed α-subunit, in
case of Gq for example activates an effector, “β isoform of phospholipase C” (PLC- β),
which cleaves the membranous phospholipid “Phosphatidylinositol biphosphate” (PIP 2),
thus, separating them into Inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 will
then bind into its receptor in the endoplasmic reticulum, which will raise the levels of Ca2+
while

simultaneously

decrease

cyclic adenosine-3',5'-monophosphate

3

(cAMP).

Following, Ca2+ calmodulin will bind to calmodulin-dependent protein kinase and start
protein phosphorylation. Similarly, DAG will bind to protein kinase C and activate protein
phosphorylation. The GTPase activity of the α-subunit promotes reassociation with βγ to
terminate ligand induced signaling (9, 13, 18, 21-25).
The function of each agonist is dependent on the specific G-protein subunit i.e. Gαq’s
effector-as describe above- is PLC-β which increases IP3 (inositol-1,4,5-trisphosphate) /
DAG. Similarly, Gβγ effector is PLC-β and PI3K-γ which increase IP3/DAG and 3-PPIs,
respectively (13). Gα12/13 effector is p115-RhoGEF whose function is actin cytoskeleton
reorganization. Gαs and Gαi effector is adenylate cyclase, and upon activation of their
corresponding GPCR, the cyclic adenosine monophosphate (cAMP) levels increase or
decrease, respectively (9, 13, 18).
Other platelet agonists bind to their own GPCR; e.g. TXA2 binds to the thromboxane
receptor, which couples to Gq and G12/13 (13, 18), whereas 5-HT binds to 5HT2A Receptor, which couples with Gq (26).
Section 1.2. E-cigarettes
Electronic cigarettes/e-cigarettes are electronic nicotine delivering systems (ENDS). The
e-cigarette user generates a mixture of vapor (derives from flavored or non-flavored
liquids) and nicotine that is inhaled in the form of aerosol (27). The nicotine containing or
free liquid normally utilized in e-cigarettes is commonly known as e-liquid. For certain
types of e-cigarette devices (e.g., JUUL), the e-liquid is found in pods that are used in the
vaping process. Often, e-liquids are composed of flavoring, nicotine, glycerin, and
propylene glycol (27). Even with all existing different designs of e-cigarettes, e-cigarettes
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share common functions and compositions i.e. a cartridge (filled with e-liquid), a
rechargeable lithium battery, and a vaporization chamber (27, 28). Usually, the e-cigarette
device has a sensor in the mouth piece, which will activate the atomizer when there is
airflow (27, 28). Further, the atomizer vaporizes the e-liquid in the vaporizing chamber
and delivers the aerosol mixture to the lungs (27, 28).
Currently, there are first, second, third, and fourth generation of e-cigarettes devices.
First-generation e-cigarettes look like a traditional cigarette with no refillable cartridge and
a low voltage (3.7 volts) (28, 29). Due to its low voltage output and low nicotine delivery,
new users are more susceptible to use this device. Often, rechargeable and disposable
e-cigarettes are considered first-generation e-cigarettes (28, 30). Smaller devices like the
first-generation e-cigarettes had low battery life. Similarly, second-generation e-cigarettes
still keep a somewhat traditional cigarette look, but now with adjustable voltage (3-6 volts),
high tank capacity, and refillable cartridges (28, 30, 31). Due to its high voltage output,
users can inhale higher puff volumes compared to the first-generation. In contrast, thirdgeneration e-cigarettes now have a bulky look and are heavy, with refillable cartridges,
longer battery life/size and adjustable voltage (28, 30). Fourth-generation devices can
control temperature and airflow. Users utilizing fourth-generation devices can inhale
serious amounts of e-liquid per use (28).
Section 1.2.1. E-cigarette JUUL
With popular demand, the e-cigarette market has kept increasing, thus, new devices
continue to be manufactured. Recently, the JUUL e-cigarette brand has attained wide
popularity among smokers, non-smokers, and especially the youth (32-34). The JUUL ecigarette device is compact, low weight, user friendly, has good battery life, and creates
5

a small vapor cloud (35, 36). The JUUL e-liquid is often called the JUUL pod. Each pod
contains ~0.7ml with 3% or 5% nicotine by weight. According to JUUL labs, each JUUL
pod is composed of glycerol, propylene glycol, flavors, nicotine, and benzoic acid (37).
Currently, the JUUL e-cigarette is marketed as an e-cigarette device with a higher safety
profile than traditional cigarettes (38). However, this statement is not evidence based and
to our knowledge, there is a lack of information and studies regarding the safety profile of
the JUUL e-cigarette device in the context of cardiovascular system. The state of
regulatory laws (or lack of) for the JUUL e-cigarette is alarming as new young users
continue to use this device (32-34). To this end, it is of great importance to investigate
and establish the safety profile of JUUL e-cigarette, to not only educate the public but to
also inform new safety/ regulatory laws.
Section 1.3.1. Serotonin
Serotonin (5-Hydroxytripamine or 5-HT) is a weak agonist to platelet aggregation, yet, is
an important regulator of hemostasis and thrombosis (39). Serotonin is found in the
platelets granules and is released upon platelet activation (39). When released, serotonin
induces vasoconstriction via modulation of endothelial cells and nitric oxide(39).
Serotonin is also known to enhance platelet aggregation in the presence of other agonists
like ADP (40-42). For normal hemostasis, proper platelet activation and recruitment is
necessary. Improper recruitment and excessive aggregability of platelets can lead to
thrombosis and thromboembolism (43-46).
The 5-HT2A receptor (5-HT2AR), a subtype of 5HT2, plays an important role in platelet
function (47). In addition, 5-HT2AR is also a GPCR (48), and is involved in the
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development of different kinds of cardiovascular disorders (49, 50). Even though there is
much information known about 5HT2AR in pathogenesis of thrombotic disease (41, 4954), there are no antagonists currently available for thrombosis/platelet related clinical
use which target this specific pathway (53-55). Thus, it is vital to understand the structural
biology of 5HT2AR and signaling transduction mechanisms to develop a drug that can
modulate 5HT2AR activation.

7

CHAPTER II: JUUL E-Cigarette Increases the Risk of Thrombosis and Enhances
Platelet Function in Mice.
Section 2.1. Abstract
Background: Smoking is the main preventable cause of death in United States and is
associated with serious cardiovascular health consequences, including thrombosis
disease. In recent years, electronic-cigarettes (i.e. e-cigarettes) have attained wide
popularity among smokers, non-smokers, pregnant females, and even youth. One
particular e-cigarette that has gained popularity over the past 2 years is the JUUL. JUUL
labs has grown expeditiously to the point of attaining $150 million US dollars in retail
sales, which accounts for 40% of the e-cigarette retail market share. JUUL’s popularity is
alarming; especially among youth. Interestingly, there is no information/studies regarding
the effect of JUUL on cardiovascular diseases, specifically in the context of modulation of
platelet activation. Thus, it is important to discern the cardiovascular disease health risks
associated with JUUL. Methods: We utilized a passive e-vapeTM vapor inhalator system
where C57BL/6J mice (10-12 weeks old) were exposed to JUUL e-cigarette vape/smoke.
Menthol flavored JUUL pods containing 5% nicotine by weight were used as the e-liquid.
Mice were exposed to a total of 70 puffs per day for 2 weeks; 3 secs puff duration, 25
secs puff interval, and 50 ml puff volume. We analyzed the effects of JUUL exposed mice
relative to those exposed to clean air, in the context of platelet function in vitro and
thrombogenesis in vivo. Results: Our results indicate that short-term exposure to JUUL
e-cigarette causes hyper-activation of platelets in vitro and shortens the thrombus
occlusion as well as hemostasis/bleeding time. Conclusion: Our findings show for the
first time that short-term exposure to JUUL E-cigarette can increase the risk of
8

thrombogenic events and can alter physiological hemostasis; in part by modulating
platelet function; in mice.
Section 2.2. Introduction
It is well established that tobacco smoking is associated with cardiovascular
disease/CVD, which is the leading cause of death in the world (1, 56, 57). Being the single
most preventable risk factor for the development of CVD (57, 58), traditional cigarette
smoking/usage has declined and new products have been introduced into the market (5962). To this end, electronic-cigarettes (e-cigarettes) have attained wide popularity in
recent years, due to the perception of being a safer option/alternative relative to tobacco
smoking, with minimal or no harm (38). As the e-cigarette market keeps growing at a fast
pace, hundreds of devices/models continue to be invented. One particular e-cigarette
device that has gained significant popularity over the past 2 years is known as “JUUL”
(32-34). JUUL sales have grown expeditiously to the point of attaining $150 million US
dollars in retail sales, which accounts for 40% of the e-cigarette retail market share (63).
It has a novel slim USB-like design that makes it easy to use and carry, and it also comes
with prefilled e-liquid pods and is available in various flavors (64, 65). The unique design
and appealing nature of the device and flavors along with the advertisement/marketing
campaign attracts smokers, non-smokers, and even the youth (35, 36, 66). Of particular
concern is the fact that the youth has the highest increase in e-cigarettes usage (67, 68),
especially the JUUL device (65, 69-72). Thus, over 3.6 million kids have used e-cigarettes
in 2018, which corresponds to 78% and 48% increase in usage among high school and
middle school students, respectively, compared to 2017 (67, 68, 73). In fact, the Food
and Drug Administration (FDA) raised concerns regarding JUUL’s popularity in young
9

communities and the potential for creating a new generation of smokers (38, 74). Based
on these considerations, it is paramount to establish the safety of exposure to JUUL ecigarette, including in the context of cardiovascular disease. To this end, limited studies
have evaluated the impact of traditional e-cigarettes on the genesis of thrombosis-based
CVD. Nonetheless, we have previously shown that short-term e-cigarette exposure can
alter physiological hemostasis and increase the risk of thrombosis, via modulating platelet
function in mice (75). Additionally, a recent crossover study that was conducted on
tobacco smokers and nonsmokers found that acute use of e-cigarettes enhanced platelet
aggregation (76). To our knowledge, there is no information regarding the impact of JUUL
e-cigarette on the cardiovascular system.
JUUL has certain/unique features and does not resemble the traditional e-cigarette as the
device is circuit and temperature controlled and generates a small cloud. Furthermore,
the e-liquid composition is also different, as it contains a nicotine salt and higher
concentrations of nicotine (3% and 5% by volume) (64, 77). According to JUUL labs, each
e-liquid JUUL pod is intended to give 200 puffs, which equals one pack of combustible
cigarettes in terms of the delivered nicotine concentration (78). Furthermore, the use of
the salt results in higher amount of nicotine being delivered to users. To this end, a recent
study did in fact show that youth are exposed to higher concentrations of nicotine when
they use JUUL, compared to combustible cigarettes (64, 79). Therefore, we characterized
the impact of JUUL exposure on thrombogenesis and platelet function- in mice- utilizing
a whole-body exposure protocol that mimics real life JUUL users. Our findings
demonstrate that two weeks exposure to JUUL e-cigarette increases the risk of
thrombosis and enhances hemostasis, in mice. In addition, JUUL exposure enhances
10

platelet activity as reflected by enhanced aggregation, secretion, and integrin GPIIb/IIIa
activation. These findings indicate that the JUUL e-cigarette is not safe as people believe.
Further studies are needed to shed more light on its harmful effects to the cardiovascular
health.
Section 2.3. Materials and Methods
Section 2.3.1. Materials and Reagents
JUUL device and JUUL Pods (5% nicotine and menthol flavoring) were purchased from
the JUUL Labs, Inc. (www.juul.com). Stir bars and other disposables were purchased
from Chrono-Log Corporation (Havertown, PA). ADP and thrombin were purchased from
Sigma Aldrich (St. Louis, MO). Fluorescein isothiocyanate (FITC)-conjugated anti-Pselectin and FITC-conjugated Annexin V were purchased from Cell Signaling Technology,
Inc (Danvers, MA). Phycoerythrin (PE)-conjugated JON/A antibody was obtained from
Emfret analytics (Würzburg, Germany). The Mouse/Rat Cotinine ELISA kit was from
Calbiotech (El Cajon, CA). Platelet count was determined using an automated
hematology analyzer (Drew Scientific Dallas, TX). The primary antibodies (ERK, pERK,
Akt, and pAkt) were purchased from cell signaling Technology, Inc. (Danvers, MA). Other
reagents were of analytical grade.
Section 2.3.2. Animals
C57BL/6J (10-12-week-old male) mice were obtained from Jackson Laboratory (Bar
Harbor, ME). Mice were housed in groups of 1–5 at 24 ° C, under 12/12 light/dark cycles,
with access to water and food ad libitum. All animal experimental protocols were approved
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by the Institutional Animal Care and Use Committee (IACUC) of The University of Texas
at El Paso.
Section 2.3.3. JUUL E-cigarette Exposure Protocol
C57BL/6 mice (10-12 weeks old males) were exposed to a total of 70 puffs per day for a
period of 2 weeks. Puff duration was 3 seconds (puff volume was 50 ml) with puff intervals
of 25 seconds. These conditions mimic real-life exposure scenarios (75, 80-82). As for
the control mice, they are matched in terms of age and sex to the JUUL e-cigarette
exposed mice and were exposed to clean air. The JUUL e-cigarette exposed and control
mice were deprived of food and water during exposure. The apparatus used to generate
the aerosol (e-vape) is a custom-made bench-top e-VapeTM vapor inhalation system for
rodents (La Jolla Alcohol Research, Inc). The system has four chambers each connected
to its own “mode box”. The “mode box” is custom made with a USB outlet to be compatible
with the JUUL device, and is connected to a controller that allows us to automatically predetermine the following experimental conditions: the puff time/duration, puff interval (time
between puffs), and/or number of puffs. In terms of the JUUL pods, each contained 0.7
mL of e-liquid with 5% nicotine by weight and menthol flavoring (32, 83).
Section 2.3.4. Methods
The data, analytic methods, and study materials will be made available to other
researchers for purposes of reproducing the results or replicating the procedure. Because
there are no speciﬁc study materials per se, requests for data, and the vaping protocol
will be honored on a case-by-case basis.
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Section 2.3.5. Cotinine Assay
The urinary levels of cotinine, a metabolite of nicotine, were measured in both JUUL and
clean air–exposed mice, using the Cotinine Direct ELISA kit as per the manufacturer’s
instructions.
Section 2.3.6. In vivo Thrombosis Model
JUUL e-cigarette and clean air exposed mice were anesthetized by IP injections of
avertin. Then, the left carotid artery was exposed and cleaned, and baseline carotid artery
blood flow was measured with Transonic micro-flowprobe (0.5 mm, Transonic Systems
Inc., Ithaca, NY). After stabilization of blood flow, 7.5% ferric chloride (FeCl3) was applied
to a filter paper disc (1-mm diameter) that was immediately placed on top of the artery for
3 min. Blood flow was continuously monitored for 30 min, or until blood flow reached
stable occlusion (zero blood flow for 2 min). Data was recorded and time to vessel
occlusion was calculated as the difference in time between stable occlusion and removal
of the filter paper (with FeCl3). An occlusion time of 30 min was considered as the cut-off
time for the purpose of statistical analysis.
Section 2.3.7. Tail Bleeding Time Assay
Hemostasis was examined using the tail transection technique. Mice were anesthetized
and placed on a 37 °C homeothermic blanket. Tail was transected 5 mm from the tip using
a sterile scalpel. After transection, the tail was immediately immersed in saline (37 °C,
constant temperature) and the time to bleeding cessation was measured. Bleeding time
of 15 min was considered as the cut-off time for the purpose of statistical analysis.
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Section 2.3.8. Murine Platelet-Rich Plasma Preparation
Clean air– or JUUL e-cigarette–exposed mice were anesthetized, and blood was
collected from the heart. Coagulation was inhibited by 0.38% sodium citrate solution
(Fisher Scientiﬁc, Hampton, NH). Blood was centrifuged (237g for 15 minutes) at room
temperature, and the platelet-rich plasma was then collected. Platelets were counted with
the HEMAVET® and their count adjusted to 7 x107 platelets/mL before each experiment.
Section 2.3.9. Washed Platelet Preparation
Washed platelets were prepared as described previously (21, 84, 85). Blood was drawn
from C57BL/6J mice (10–12 weeks old) as discussed above and mixed with phosphatebuffered saline, pH 7.4, incubated with PGI2 (10 ng/mL; 5 minutes), followed by
centrifugation at 237x g for 10 minutes at room temperature. Platelet-rich plasma was
recovered, and platelets were pelleted at 483x g for 10 minutes at room temperature. The
pellets were resuspended in HEPES/ Tyrode buffer (20 mmol/L HEPES/KOH, pH 6.5,
128 mmol/L NaCl, 2.8 mmol/L KCl, 1 mmol/L MgCl2, 0.4 mmol/L NaH2PO4, 12 mmol/L
NaHCO3, 5 mmol/L Dglucose) supplemented with 1 mmol/L EGTA, 0.37 U/mL apyrase,
and 10 ng/mL PGI2. Platelets were then washed and resuspended in HEPES/Tyrodes
(pH 7.4) without EGTA, apyrase, or PGI2. Platelets were counted using the HEMAVET®
and adjusted to the indicated concentrations.
Section 2.3.10. In vitro Platelet Aggregation
Platelet-rich plasma from clean air– or JUUL e-cigarette–exposed mice was activated
with 1 μM ADP or 0.1 U/ml thrombin. Platelet aggregation was measured by the
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turbidometric method using a model 700 aggregometer (Chrono-Log Corporation). Each
experiment was repeated at least 3 times, with blood pooled from 5-8 mice each time.
Section 2.3.11. Flow Cytometric Analysis
Flow cytometric analysis was performed as previously prescribed (21). Washed platelets
were stimulated with ADP (1 μM), or thrombin (0.1 U/ml). The reactions were stopped by
fixing the platelets with 2% formaldehyde for 30 min at room temperature. Finally,
platelets were incubated with FITC-conjugated Annexin V and anti– P-selectin, or Jon/A
PE-conjugated antibodies at room temperature for 30 min in the dark. Finally, the platelets
were diluted 2.5-fold with HEPES/ Tyrode buffer (pH 7.4). The samples were transferred
to FACStubes and fluorescent intensities were measured using a BD Accuri C6 flow
cytometer and analyzed using CFlow Plus (BD Biosciences, Franklin Lakes, NJ).
Section 2.3.12. Immunoblotting
Immunoblot was carried out as described before (85). Brieﬂy, clean air– or JUUL–
exposed washed platelets were stimulated with ADP (1 μM) or thrombin (0.1 U/ml) for 3
minutes followed by lysis with 1X sample buffer. Next, proteins were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to Immobilon-P
PVDF membranes (Bio-Rad, Hercules, CA). Membranes were then probed with the
primary antibodies (ERK, pERK, Akt, and pAkt) and visualized with horseradish
peroxidase–labeled anti-rabbit or anti-mouse immunoglobulin G as required. The
antibody binding was detected using enhanced chemiluminescence substrate (Thermo
Scientiﬁc, Rockford, IL). Images were obtained with ChemiDoc MP Imaging System (BioRad, Hercules, CA), and quantiﬁed with Image Lab software Version 4.1 (Bio-Rad).
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Section 2.3.13. Statistical Analysis
All experiments were performed at least three times. Analysis of the data was performed
using GraphPad PRISM statistical software (San Diego, CA) and presented as mean ±
SD. The Mann-Whitney test was used for the evaluation of differences in mean occlusion
and bleeding times. Analysis was also conducted using the t-test and/or one-way ANOVA
with Tukey’s multiple regression comparison as post hoc were used as applicable.
Significance was accepted at P<0.05, unless stated otherwise.
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Section 2.4. Results
Section 2.4.1. JUUL E-Cigarette Exposure Systematically Delivers Nicotine
In order to verify if our whole-body exposure model does systematically deliver nicotine
to the mice, cotinine was measured due to the fact that it is a major metabolite of nicotine,
thus serving as a marker of nicotine delivery (86, 87). Therefore, urinary cotinine levels
were measured using ELISA, and our data showed significant levels of cotinine in the
urine of JUUL e-cigarette exposed mice, whereas it was undetectable in the clean air
control mice (Fig. 2.1.).

Figure 2.1. JUUL exposure results in systemic delivery of nicotine (cotinine).
Urinary cotinine levels from JUUL and clean air exposed mice (clean air, n = 5; and JUUL,
n = 5; ****P<0.0001).
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Section 2.4.2. JUUL E-Cigarette Exposed Mice Exhibit Enhanced Physiological
Hemostasis and Thrombus Formation
In terms of characterizing the negative CV effects of the JUUL e-cigarette, we initially
investigated its capacity to modulate physiological hemostasis by utilizing the tail bleeding
time assay. Our findings show that JUUL-exposed mice have significantly shortened tail
bleeding time compared to mice exposed to clean air (Fig. 2.2.A). Next, we examined the
thrombotic effect of JUUL e-cigarette exposure by implementing the carotid artery injuryinduced thrombosis model. We observed that JUUL-exposed mice have remarkably
shortened occlusion time compared to their controls (Fig. 2.2.B). These results indicate
that JUUL e-cigarette exposure increases the risk of thrombosis and enhances
physiological hemostasis.

Figure 2.2. JUUL exposure shortens the tail bleeding and occlusion times. (A) JUUL
e-cigarette and clean air exposed mice were subjected to the tail bleeding time
assessment. Each point represents the tail bleeding time of a single animal (clean air, n
= 7; and JUUL, n = 7; ***P<0.001). (B) JUUL e-cigarette and clean air exposed mice were

18

subjected to the ferric chloride-induced thrombosis model. Each point represents the
occlusion time of a single animal (clean air, n = 5; and JUUL e-cigarette, n = 5; **P<0.01).
Section 2.4.3. JUUL E-Cigarette Exposure Enhances ADP-, and Thrombin-Induced
Platelet Aggregation
We have previously shown that e-cigarette exposure modulates platelet function (75).
Thus, we sought to investigate whether the JUUL e-cigarette exposure would also
produce platelet effects. Consequently, we assessed the effects of JUUL e-cigarette
exposure on platelet aggregation induced by “two” separate G-protein coupled receptors,
namely those activated by ADP and thrombin. Our data revealed that exposure to JUUL
e-cigarettes results in higher ADP-induced platelet aggregation, in comparison to clean
air control platelets (Fig. 2.3.A). Similarly, thrombin-induced platelet aggregation was also
elevated/enhanced in the JUUL e-cigarette exposed platelets (Fig. 2.3.B). These results
suggest that JUUL e-cigarette exposure can lead to platelet hyperactivity.

Figure 2.3. Platelet aggregation is enhanced in JUUL exposed mice. Platelets from
JUUL e-cigarette and clean air exposed mice were stimulated with (A) ADP (1 μmol/L),
or (B) thrombin (0.1 U/ml). The aggregation response was measured using an
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aggregometer. Each experiment was repeated 3 times, with blood pooled from 5-8 mice
each time.
Section 2.4.4. JUUL E-Cigarette Exposure Enhances ADP-, and Thrombin-Induced
Platelet Secretion
Agonist-induced exocytosis or granules release plays a very important role in the
amplification of initial platelet activation during primary hemostasis (88-90). Accordingly,
we determined if JUUL e-cigarette exposure exerts any impact on dense and α granule
secretion. In line with our aggregation data, we observed enhanced ATP secretion from
platelets obtained from the JUUL e-cigarette exposed mice in response to ADP (Fig.
2.4.A) and thrombin (Fig. 2.4.B) agonist stimulation, when compared to platelets from the
clean air exposed mice. Moreover, JUUL e-cigarette exposed platelets had significantly
higher ADP-, and thrombin-triggered P-selectin expression (Fig. 2.4.C).

Figure 2.4. Platelet dense and α granule secretion are enhanced in JUUL exposed
mice. Platelets from JUUL e-cigarette and clean air exposed mice were incubated with
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luciferase luciferin (12.5 μL), then were stimulated with (A) ADP (1 μmol/L), or (B)
thrombin (0.1 U/ml). ATP release (dense granules) was detected as luminescence and
measured by a lumi aggregometer. (C) Platelets from JUUL e-cigarette and clean air
exposed mice were washed, before stimulation with 1 μmol/L ADP, or 0.1 U/ml thrombin.
Platelets were incubated with fluorescein isothiocyanate conjugated CD62P antibody,
and the fluorescent intensities were measured by flow cytometry. The average mean
fluorescence intensities are showed (****P<0.0001). Each experiment was repeated 3
times, with blood pooled from 5-8 mice each time.
Section 2.4.5. JUUL E-Cigarette Exposure Enhances Agonist-Induced Integrin
GPIIb/IIIa Activation and Phosphatidylserine Exposure
We next investigated if there is a commensurate increase in integrin GPIIb/IIa (αIIbβ3)
activation in the JUUL e-cigarette exposed platelets, given their increased aggregation
phenotype (91, 92). We found that JUUL e-cigarette exposed platelets had an enhanced
agonist-mediated activation of GPIIb/IIa, when compared to clean air exposed platelets
(Fig. 2.5.A). Moreover, agonist-mediated phosphatidylserine (PS) expression, which is a
critical element for efficient activation of the coagulation cascade and essential aspect of
clot formation, was also found to be enhanced in the JUUL platelets (Fig. 2.5.B).
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Figure 2.5. Integrin GPIIb/IIIa activation and phosphatidylserine (PS) exposure are
increased in JUUL exposed mice. Platelets from JUUL e-cigarette and clean air
exposed mice were washed, before stimulation with 1 μmol/L ADP, or 0.1 U/ml thrombin.
Platelets were incubated with phycoerythrin-conjugated JON/A antibody, and the
ﬂuorescent intensities were measured by ﬂow cytometric analysis (A); (*****P<0.0001).
Platelets were incubated with ﬂuorescein isothiocyanate–conjugated Annexin V antibody,
and the ﬂuorescent intensities were measured by ﬂow cytometric analysis (B). Average
mean ﬂuorescence intensities shown (****P<0.0001). Each experiment was repeated 3
times with blood collected from 5-8 mice each time.
Section 2.4.6. JUUL E-Cigarette Exposure Enhances Akt and ERK Activation
Finally, and in light of the functional data indicating platelet hyperactivity, we sought to
determine if biochemical markers of platelet activation would also be elevated as a result
of JUUL e-cigarette exposure. Indeed, Akt and ERK phosphorylation were found to be
elevated in the JUUL platelets, in response to ADP (1 μM; Fig. 2.6.).
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Figure 2.6. Platelet Akt (protein kinase B) and ERK (extracellular signal-regulated
kinases) activation (phosphorylation) is enhanced in JUUL exposed mice. Platelets
from JUUL and clean air–exposed mice were prepared and washed. (A) Platelets were
stimulated with 1 μmol/L adenosine diphosphate (ADP) for 3 min, and proteins were lysed
using 1×sample buffer. Proteins were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis before being subjected to immunoblotting with antiAkt, antipAkt (Ser473), anti-ERK, and anti-pERK antibodies. (B) Data quantification of
ADP-induced ERK and Akt phosphorylation (****P<0.0001; ***P<0.001). Each
experiment was repeated at least 3 times with blood collected from a group of 5-8 mice
each time.
In summary, our data provides evidence that two week exposures to JUUL ecigarettes vapes results in enhanced in vitro and in vivo platelet function, which was also
confirmed by biochemical means.
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Section 2.5. Discussion
The JUUL e-cigarette has been gaining popularity at an alarming rate since its
introduction into US market in 2015, and by 2018 has overtaken more than half of the ecigarette market (33, 35, 93). In this connection, it was marketed by JUUL labs, the
manufacturer, as an e-cigarette device with a higher safety profile than traditional
cigarettes (38); which we know is not supported by evidence. It has a unique USB- like
design and comes with pre-filled pods that makes it appealing to use and easy to carry.
Consequently, its use increased significantly among smokers and non-smokers, but also
especially (and of more concern) among the youth (62, 83, 94). In term of the
cardiovascular safety of e-cigarettes, we recently showed that exposure to traditional ecigarette enhances physiological hemostasis and increases risk of thrombosis via
modulating platelet function, in adult mice (75). However, whether the JUUL e-cigarette
exerts negative health effects, namely increases the risk of thrombosis-dependent
cardiovascular disorders remains to be investigated. Indeed, given the wide popularity
and the unique features of JUUL e-cigarette, it is paramount to establish the
cardiovascular safety of these devices. Thus, this issue was investigated by employing a
mouse whole-body in vivo exposure model and a protocol that mimics real-life exposure
scenarios of a daily JUUL user (69). It has been recently reported that daily JUUL users
consume 10 pods per one month, which equals one pod every three days. Since each
pod can generate 200 puffs, we choose to expose mice to 70 puffs per day to resemble
human settings (69). Given that JUUL e-cigarette has only recently been introduced into
the market, human studies related to its effect on the general health, and the
cardiovascular system (CV) in specific are non-existent. Thus, mouse models can serve
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as a readily available and practical tools to provide rather rapid answers to some of the
safety questions, which may need months and/or years to establish in human studies.
Furthermore, human studies are complicated by the variability of e-liquids and various
flavors used, patterns of use, user’s experience, and the concomitant use of other tobacco
products, which makes it hard to draw a conclusion. Notably, given these challenges in
human studies, the current mouse model gives flexibility in mimicking many aspects of
human use, and the literature does support the fact that mouse studies do “map” very
well to humans in the context of tobacco exposure (75, 80-82).
Initially, we validated our model by measuring the levels of cotinine, a key biomarker of
nicotine exposure (95, 96), in urine samples of JUUL e-cigarette and clean air exposed
mice. The cotinine levels increased significantly in JUUL e-cigarette exposed mice,
whereas it was undetectable in the clean air exposed mice. Indeed, these high cotinine
levels are not surprising given the fact that each JUUL pod (200 puffs) contains a high
concentration of nicotine (5% by weight); which is equivalent to 1 pack of cigarettes (97,
98). Furthermore, the use of nicotine salt results in high amounts of nicotine being
delivered to users as the salt masks the bitter taste of nicotine. Consistent with our finding,
a recent study showed that youth are exposed to higher concentrations of nicotine when
they use JUUL, compared to combustible cigarettes (99). Taken together, JUUL ecigarette delivers a high amount of nicotine to users, which raises concerns regarding
potential negative impact of nicotine, especially among youth users (98); which warrants
investigation. Of note, while e-cigarettes have potential toxicants, such as nicotine,
propylene glycol/glycerol, and flavors (100, 101), the JUUL pods contain nicotine salts,
whose toxicity is virtually unknown.
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As for the effects of JUUL on the genesis of thrombosis-dependent CVD, studies are
non-existent. Our mouse model data demonstrated for the first time that exposure to
JUUL (two weeks) increases the risk of thrombosis, as reflected by the prolonged
occlusion time compared to control mice. Additionally, JUUL exposure altered
physiological hemostasis as evidenced by the shortened the tail bleeding time. A similar
prothrombotic phenotype was also observed in short term exposure to traditional ecigarettes (75). In support of these findings, a recent meta-analysis concluded that ecigarettes should not be marketed as “cardiovascularly” safe devices as more evidence
needs to be collected (102). Collectively, our findings clearly indicate that JUUL ecigarettes pose a negative cardiovascular (thrombotic) health impact contrary to the
claimed safety by JUUL labs (38).
In light of the observed prothrombotic phenotype and since platelets are key players in
thrombus formation (103, 104), we sought to investigate the impact/effects of JUUL ecigarette on platelet function. Our data revealed that JUUL exposure enhances platelet
function,

including

aggregation,

secretion,

integrin

GPIIb/IIIa

activation,

phosphatidylserine (PS) exposure, compared to clean air. Moreover, the phosphorylation
of Akt and ERK, which serve as biochemical markers of platelet activity, was enhanced
in response to JUUL e-cigarette exposure. These data indicate that JUUL e-cigarette
exposed platelets are hyperactive, which could explain- at least partially, the observed
prothrombotic phenotype. Supportingly, our previously published data with traditional ecigarette exposure showed similar trends of increased platelet function, in mice (75).
These data are also consistent with a recent human study in which acute e-cigarette use
was found to increase platelet activation (76).
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Section 2.6. Conclusion
In conclusion, our study revealed for the first time that whole-body JUUL e-cigarette
exposure alters physiological hemostasis and increases the risk of thrombosis, in mice;
in part by modulating platelet function. Importantly, these findings provide clear/initial
evidence that the JUUL e-cigarette is not safe as currently claimed, and should be the
focus of further investigations. Additionally, our study should help increase awareness of
the negative health consequences of these devices, especially among the youth,
including those who had never smoked before but tried JUUL with the perception that
these devices are safe. Given the current epidemic of e-cigarette use, specifically JUUL,
we expect our data to help guide/inform the FDA in instituting and implementing stricter
regulations to limit the use of JUUL devices.
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CHAPTER III: A Novel Antibody Targeting The Second Extracellular Loop of The
Serotonin 5-HT2A Receptor Inhibits Platelet Function.
Section 3.1. Abstract
Background: Serotonin (5-hydroxytryptamine or 5-HT) is known to be a weak agonist
involved in thrombus formation. 5-HT cannot induce platelet aggregation on its own. Yet,
when the secreted 5-HT binds to its G-protein Coupled Receptor (GPCR; i.e. 5HT2AR), 5HT acts to amplify platelet functional responses (e.g., aggregation). Thus, 5HT2AR
mediated responses are more involved in the secondary amplification of platelet
aggregation in the growing thrombus. Therefore, 5-HT can be seen as a weak inducer of
platelet activation, but it is an important amplifier of aggregation triggered by agonists
such as ADP, collagen, and epinephrine, thereby enhancing thrombogenesis. 5HT 2ARs
are of clinical interest to the medical community as they are implicated in cardiovascular
diseases. Efforts to develop antagonists for 5HT2AR as therapy in cardiovascular
diseases have thus far failed due to these reagents having deleterious side-effects and/or
to lack of selectivity. Methods: In light of research efforts that identified that the 5HT2AR
ligand binding domain lies in the second extracellular loop (EL2; P209-N233), we developed
an antibody, i.e. referred to as 5HT2ARAb against the EL2 region Q216-N233, and
characterized its pharmacological activity. Thus, we utilized C57BL/6J mice (10-12 weeks
old) to analyze the inhibitory effects of the 5HT2ARAb on platelet activation in vitro, ex
vivo, and on thrombogenesis in vivo. Results: Our results indicate that the 5HT2ARAb
inhibits platelet aggregation in vivo, ex vivo, and that it prolongs the thrombus occlusion
time, but it did not modulate the tail bleeding time, in mice. Conclusion: Our findings
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document that 5HT2ARAb exhibits platelet function blocking-activity and protects against
thrombogenesis without impairing normal hemostasis.
Section 3.2. Introduction
Platelets are indispensable to physiological hemostasis (105, 106). When a blood vessel
is injured, platelets are able to interact with the unmasked/exposed subendothelial matrix,
which thereby leads to platelet adherence and activation (107, 108). Consequently, a
number of intraplatelet signaling pathways are triggered, which result in a rise in
intracellular calcium levels; secretion of granule content (109, 110) (e.g., serotonin/5HT
and ADP); as well as liberate arachidonic acid (AA) from the membrane phospholipids
(109). While ADP in turn interacts with its P2Y1 and P2Y12 G-protein coupled receptors
(GPCRs), AA is acted upon by cyclooxygenase (COX-1) to produce PGH2, which is
metabolized by thromboxane A2 synthase into TXA2 (111, 112). The latter binds to its own
GPCR (113-115), and thereby activates platelets. Moreover, another important aspect of
platelet signaling involves binding of the secreted serotonin (5-hydroxytriptamine or 5-HT)
to its platelet 5HT2AR GPCR in order to amplify platelet functional responses (e.g.,
aggregation) (116). Thus, several positive feedback loops are initiated to intensify the
extent of aggregation by means of enhancing platelet responsiveness as well as recruiting
other platelets to the site of injury, in order to achieve formation of a stable clot (116).
Although platelet activation is a vital component of hemostasis, improper activation and
aggregation may lead to thrombosis and thromboembolism (43-46). Consequently, antithrombotic drug development efforts have focused on the discovery of reagents/drugs
that modulate activation of platelets by their agonists (117, 118). The serotonin 5HT2AR,
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which couples to Gq (119, 120), recently has been under drug targeting scrutiny as of late
(55). While 5HT itself is a weak stimulator of platelet activation, it does however potentiate
aggregation triggered by separate agonists, thereby enhancing thrombogenesis (24, 25).
Another attractive aspect of targeting 5HT2AR for therapeutic purposes centers on the
notion that its anti-thrombotic activity and bleeding time adverse events can be separated
(which has been demonstrated previously albeit the mechanism remains unknown to date
(53-55). To this end, a host of antagonists for 5HT2AR were developed throughout the
years and investigated for their pharmacological activity (53-55, 121-123). Unfortunately,
none have been approved for clinical use due to significant toxicity, and/or lack of
selectivity for 5HT2AR, amongst others. One discernable reason for failure of 5HT2AR
antagonism thus far seems evident, as these agents were designed empirically, without
“regard” to the 5HT2AR binding domains information. Therefore, it is critical to understand
the structural biology and signaling of 5HT2AR. In this connection, mapping of the 5HT2AR
ligand binding domain revealed that the ligand binding domain resides in the second
extracellular loop (EL2) of the receptor protein, namely (P209-N233) (124-126).
Based on these considerations, in the present study, we custom-made and characterized
the antiplatelet activity of a potentially 5HT2AR-function-blocking antibody that targets its
EL2 region (abbreviated as 5HT2ARAb). Our studies revealed that this 5HT2ARAb indeed
inhibited serotonin-enhanced ADP-induced human/mice platelet aggregation in vitro, and
ex vivo in mice. Also, 5HT2ARAb inhibited serotonin-enhanced ADP-stimulated platelet
secretion, glycoprotein (GP) IIb/IIIa activation, and phosphatidylserine (PS) exposure.
The 5HT2ARAb was also found to displace binding of the radiolabeled 5HT2AR antagonist
[3H]Ketanserin from its binding sites; this effect was reversed by preabsorption of
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5HT2ARAb with its cognate peptide (Q216-N233). Moreover, as for its in vivo activity, mice
treated with 5HT2ARAb had a significantly prolonged occlusion time, but their bleeding
time was no different from that of the controls.
Section 3.3. Materials and Methods:
Section 3.3.1 Materials and Reagents
Serotonin hydrochloride, and ADP were obtained from Sigma Aldrich (St. Louis, MO). Stir
bars and other disposables were from Chrono-Log (Havertown, PA). FITC-conjugated
Annexin V, anti–P-selectin, and PAC-1 antibodies were purchased from Cell Signaling
Technology, Inc. (Danvers, MA). The 5HT2A receptor targeting polyclonal antibody,
designated 5HT2ARAb, was custom made and antigen-affinity purified by a commercial
vendor, Abbiotec Inc (San Diego, CA). Platelet count was determined using an automated
hematology analyzer (Drew Scientific Dallas, TX).
Section 3.3.2. Animals
C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME). Mice were
housed in groups of 1–4 at 240C, under 12/12 light/dark cycles, with access to water and
food ad libitum. All experiments involving animals were perform in compliance with the
institutional guidelines, and were approved by the Institutional Animal Care and Use
Committee.
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Section 3.3.3. Human and Murine Platelet Preparation
Blood was drawn from healthy volunteers who denied taking any medication for 1 week
prior to collection, or from C57BL/6 mice (8–10 weeks old). Mice were anesthetized and
blood was collected from the heart. Coagulation was inhibited by 3.8% w/v sodium citrate
solution (1 part sodium citrate to 9 parts blood). Human or mouse platelet rich plasma
(PRP) was obtained by centrifugation at room temperature. Platelets were counted with
an automated hematology analyzer and their count adjusted to 7x10 7 platelets/ml, prior
to each experiment. Washed human platelets were prepared as described in Karim et al
(21). PRP was isolated in the presence of 0.37 units/ml apyrase and 10 ng/ml PGI2 by
centrifugation at 237g for 10 min at 20 °C. PRP was centrifuged at 483g for 10 min, and
pelleted platelets were resuspended in HEPES/Tyrode’s buffer (20 mMHEPES/NaOH,
pH 6.5, 128 mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 5 mM D-glucose, 12 mM NaHCO3, 0.4
mM NaH2PO4) containing 1 mM EGTA, 0.37 units/ml apyrase, and 10 ng/ml PGI 2.
Platelets were washed and resuspended in HEPES/Tyrode’s buffer (pH 7.4) without
EGTA, apyrase, or PGI2. The final platelet counts were adjusted to 7x107 platelets/ ml,
unless otherwise indicated.)
Section 3.3.4. In vitro Platelet Aggregation
Human PRP was incubated with the 5HT2ARAb for 5 min prior to experiments, except in
case of the controls. Platelets were then activated with submaximal concentration of ADP
(1 μM), in the presence or absence of 15 μM serotonin. Control experiments were
conducted using the ADP agonist alone (10 μM). Platelet aggregation was measured by
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the turbidometric method using a model 700 aggregometer (Chrono-Log Corporation,
Havertown, PA). Each experiment was repeated at least 3 times, with blood collected
from three different human donors, or pooled together from at least eight mice each time.
Section 3.3.5. Ex vivo Platelet Aggregation
Mice were injected with the 5HT2ARAb (150 mM) or vehicle (deionized water) using the
tail vein route once daily for 5 days; in an attempt to mimic chronic administration of these
drugs in patients. Mice were sacrificed one hour post last injection, and their blood
collected. Platelets (with counts adjusted as described before) were stimulated with 1 μM
ADP in the presence or absence of 15 μM serotonin, and platelet aggregation was
measured. Control experiments were conducted using the ADP agonist alone (10 μM).
Each experiment was repeated at least 3 times, with blood pooled from at least eight mice
each time.
Section 3.3.6. Flow Cytometric Analysis
Human platelets (2x108) were incubated in the presence or absence of 5HT2ARAb (150
nM) for 5 minutes. Platelets were stimulated with 1 μM ADP in the presence or absence
of 15 μM serotonin. Control experiments were conducted using the ADP agonist alone
(10 μM). The reactions were stopped by fixing the platelets with 2% formaldehyde for 30
min at room temperature. Finally, platelets were incubated with FITC-conjugated Annexin
V, anti– P-selectin, or PAC-1 antibodies at room temperature for 30 min in the dark.
Finally, the platelets were diluted 2.5-fold with HEPES/ Tyrode buffer (pH 7.4). The
samples were transferred to FACStubes and fluorescent intensities were measured using
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a BD Accuri C6 flow cytometer and analyzed using CFlow Plus (BD Biosciences, Franklin
Lakes, NJ).
Section 3.3.7. In vivo Thrombosis Model
These studies were performed as described previously (127, 128). Briefly, mice 8–10
weeks old received tail vein injections of the 5HT2ARAb (150 nM) or vehicle once daily for
5 days, and were anesthetized with isoflurane. Then, the left carotid artery was exposed
and cleaned, and baseline carotid artery blood flow was measured with Transonic microflowprobe (0.5 mm, Transonic Systems Inc., Ithaca, NY). After stabilization of blood flow,
7.5% ferric chloride (FeCl3) was applied to a filter paper disc (1-mm diameter) that was
immediately placed on top of the artery for 3 min. Blood flow was continuously monitored
for 30 min, or until blood flow reached stable occlusion (zero blood flow for 2 min). Data
was recorded and time to vessel occlusion was calculated as the difference in time
between stable occlusion and removal of the filter paper (with FeCl 3). An occlusion time
of 30 min was considered as the cut-off time for the purpose of statistical analysis.
Section 3.3.8. Tail Bleeding Time
Mice were tail vein injected with the 5HT2ARAb (150 nM) or vehicle once daily for 5 days,
before their hemostasis response was examined using the tail transection technique (127,
128). Briefly, mice were anesthetized and placed on a 37 °C homeothermic blanket. The
tail was transected 5 mm from the tip using a sterile scalpel. After transection, the tail was
immediately immersed in saline (37 °C, constant temperature) and the time to bleeding
cessation was measured. Bleeding time of 15 min was considered as the cut-off time for
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the purpose of statistical analysis.
Section 3.3.9. Radioligand Binding Displacement
Resuspended platelets (1 x 109 platelets/ml) were prepared as previously described(115,
129), before they were incubated with 2 nM [3H]ketanserin at room temperature for 10
min. Next, increasing concentrations of the displacing 5HT2ARAb (10 nM-1 μM) were
added for an additional 45 minutes. Next, the [ 3H]ketanserin bound platelets were
captured by running through 0.45 micron Millipore filters over a vacuum suction unit. The
filters were then washed once and counted for radioactivity in a Beckman LS 6000 liquid
scintillation counter. To calculate the non-specific binding, the same concentration of
radio ligand was competed against 1000-fold excess of unlabeled ketanserin.
Section 3.3.10. Statistical Analysis
All experiments were performed at least three times. Analysis of the data was performed
using GraphPad PRISM 7.0 statistical software (San Diego, CA) and presented as mean
± SD. The Mann-Whitney test was used for the evaluation of differences in mean
occlusion and bleeding times. Analysis was also conducted using t-test, and similar
results were obtained. Significance was accepted at P<0.05 (two-tailed P value), unless
stated otherwise.
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Section 3.4. Results
Section 3.4.1. 5HT2ARAb Inhibits Serotonin-enhanced Human Platelet Aggregation
Our initial analysis showed that serotonin (15 μM) alone does not induce platelet
aggregation in human PRP (Fig. 3.1.A). In contrast, we did observe platelet aggregation
when stimulating with ADP (1 μM), albeit it was a “weak” response given the subthreshold
dose we used. Concurrent addition/stimulation with serotonin (15 μM) and ADP (1 μM)
on the other hand resulted in a significant platelet aggregation response (Fig. 3.1.B).
These results demonstrate that serotonin by itself cannot induce platelet aggregation, but
that it does have the capacity to enhance ADP-induced aggregation. Given that serotonin
produces its effects via the 5HT2AR, we investigated if the 5HT2ARAb that targets its
ligand-binding site would inhibit serotonin-enhanced ADP-induced platelet aggregation.
The data showed that the 5HT2ARAb did inhibit serotonin-enhanced ADP-induced platelet
aggregation, dose-dependently (100-150 nM; Fig. 3.1.B), when compared to the vehicle
control. We next confirmed that 5HT2ARAb (100 nM) does not affect the platelet activity
in the absence of serotonin, and our results revealed that it did not exert any effects on
ADP(alone; 10 M)-induced aggregation (Fig. 3.1.C). As one would predict, serotonininduced platelet shape change was inhibited by the 5HT2ARAb (100 nM; (Fig. 3.1.A).
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Figure 3.1. The 5HT2ARAb inhibits serotonin-enhanced ADP-induced human
platelet aggregation in vitro. (A) Human PRP was activated with serotonin (15 μM), with
or without pre-incubation for 5 min with 5HT2ARAb (100 nM). (B) Human PRP was
preincubated with increasing doses of 5HT2ARAb (100–150 nM) for 5 min before being
activated with a combination of ADP (1 μM) and serotonin (15 μM). (C) Human PRP was
pre-incubated with 5HT2ARAb (100 nM) for 5 min before activation with ADP (10 mM).
Each experiment was repeated at least 3 times, with blood obtained from three separate
donors.
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Section 3.4.2. 5HT2ARAb Inhibits Serotonin-enhanced Mouse Platelet Aggregation
ex vivo
We next examined investigated whether the aggregation “antagonistic” activity of the
5HT2ARAb would persist if it was injected into live mice, under multi-dosing conditions.
Thus, mice were intravenously injected once daily for 5 days with 5HT2ARAb (100-150
nM). The results revealed that serotonin-induced platelet shape change was inhibited in
the 5HT2ARAb (150 nM)-treated mice (Fig. 3.2.A). Moreover, 5HT2ARAb was found to
exert inhibitory effects on serotonin-enhanced ADP-induced aggregation in platelets from
5HT2ARAb injected mice, when compared to the vehicle control (Fig. 3.2.B). This finding
demonstrates that the inhibitory effects of the 5HT2ARAb are maintained under multidosing conditions in live animals.

Figure 3.2. The 5HT2ARAb inhibits serotonin-enhanced ADP-induced mouse
platelet aggregation ex vivo. (A) Mouse PRP obtained from 5HT2ARAb-injected (150
nM; once daily for 5 days) or control mice was stimulated with serotonin (15 μM). (B)
Mouse PRP obtained from either vehicle-injected mice (once daily for 5 days) or
5HT2ARAb-injected mice (100-150 nM; once daily for 5 days) was stimulated with
submaximal concentration of ADP (1 μM) in the presence or absence of serotonin (15
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μM). Each experiment was repeated at least 3 times, with blood pooled from at least eight
mice each time.
Section 3.4.3. The 5HT2ARAb inhibits serotonin-enhanced ADP-induced platelet
dense granule secretion in human and mouse platelets ex vivo.
Agonist-induced granules release plays a very important role in the amplification of initial
platelet activation during primary hemostasis (88-90). Accordingly, we determined if the
serotonin antibody exerts any impact on serotonin-enhanced dense granule secretion
(ATP). In line with our aggregation data, we observed 5HT2ARAb inhibition of serotoninenhanced ADP-induced ATP secretion in human platelets (Fig. 3.3.A). This inhibition was
also observed under ex vivo experimental conditions (Fig. 3.3.B).
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Figure 3.3. The 5HT2ARAb inhibits serotonin-enhanced ADP-induced secretion in
human and mouse platelets ex vivo. (A) Human PRP was incubated with luciferase
luciferin (12.5 μL) and increasing doses of 5HT2ARAb (100–150 nM) for 5 min before
being activated with submaximal concentration of ADP (1 μM) in the presence or absence
of serotonin (15 μM). (B) Mouse PRP obtained from 5HT2ARAb-injected mice (100-150
nM; once daily for 5 days) was preincubated with luciferase luciferin (12.5 μL) and
stimulated with submaximal concentration of ADP (1 μM) in the presence or absence of
serotonin (15 μM). ATP release (dense granules) was detected as luminescence and
measured by a lumi aggregometer. Each experiment was repeated at least 3 times, with
blood pooled from at least eight mice each time.
Section 3.4.4. 5HT2ARAb Inhibits Serotonin-enhanced Platelet  granule Secretion,
Glycoprotein IIb/IIIa Activation and Phosphatidylserine Exposure
We next examined whether the 5HT2ARAb exhibits inhibitory effects on separate platelet
functional responses that are also known to be enhanced by serotonin, namely  granule
secretion (P-selectin expression), GPIIb/IIIa activation and phosphatidylserine (PS)
exposure. Thus, human platelets treated with 150 nM 5HT2ARAb before being stimulated
with ADP (1 μM) alone or with a combination of ADP (1 μM) and serotonin (15 μM). As
expected, the 5HT2ARAb reversed the enhanced P-selectin expression, GPIIb-IIIa
activation and PS exposure (Fig. 3.4.A-C), whereas it had no detectable effects on those
responses induced by ADP alone. Based on these data, we conclude that 5HT2ARAb
inhibits serotonin-enhanced ADP-induced expression of several markers of platelet
activation, in addition to aggregation.
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Figure 3.4. The 5HT2ARAb Inhibits Serotonin-enhanced ADP-induced α Granule
Secretion, GPIIb/IIIa Activation and PS Exposure, in Human Platelets in vitro.
Washed platelets were incubated in the presence or absence of the 5HT2ARAb (150 nM)
for 5 minutes and then stimulated with ADP (1 μM), serotonin (15 μM) or ADP and
serotonin (1 μM and 15 μM, respectively, for 3 minutes. The reactions were stopped by
fixing the platelets with 2% formaldehyde for 30 min at room temperature. (A) Platelets
were incubated with FITC-conjugated anti–P-selectin antibody, and the fluorescent
intensity was measured by flow cytometry. (B) Platelets were incubated with FITCconjugated PAC-1 antibody, and the fluorescent intensity was measured by flow
cytometry. (C) Platelets were incubated with FITC-conjugated Annexin V antibody, and
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the fluorescent intensity was measured by flow cytometry. Each experiment was repeated
at least 3 times, with blood obtained from three separate donors.
Section 3.4.5. 5HT2ARAb Prolongs the Thrombus Occlusion Time but not the Tail
Bleeding Time
We next sought to assess the prospective of purposing the 5HT2ARAb as an antithrombosis agent, in vivo. Thus, mice were tail-vein injected with 150 nM of 5HT2ARAb
before being subjected to the carotid artery FeCl3 injury model experiment. Our results
showed a significant increase in time to occlusion in the 5HT2ARAb treated mice
compared to the vehicle controls (Fig. 3.5.A). We next tested the effects of 5HT2ARAb on
hemostasis in order to assess bleeding as a potential adverse effect. We were pleasantly
surprised that mice injected with 5HT2ARAb had a bleeding time that was no different from
the controls. (Fig. 3.5.B). Together, these results support the notion that 5HT2ARAb
protects/delays thrombus formation, and that it does so without increasing the risk of
bleeding.
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Figure 3.5. 5HT2ARAb prolongs the time to occlusion but not the tail bleeding time,
in mice. Mice were injected via the tail vein with 150 nM 5HT2ARAb, once daily for 5 days
before being subjected to the FeCl3 thrombosis and tail bleeding time models. (A) Mean
occlusion times for mice treated with 150 nM 5HT2ARAb or vehicle (n = 8). (B) Mean
bleeding times for mice treated with 150 nM 5HT2ARAb or vehicle (n = 5). Each point
represents the occlusion time or tail bleeding time of a single animal.
Section 3.4.6. 5HT2ARAb Displaces the 5HT2AR Antagonist Ketanserin from its
Binding Sites
Finally, while the 5HT2ARAb exerts inhibitory effects on serotonin-enhanced platelet
function, this is presumed to involve antagonism of the 5HT2AR. Indeed, increasing
concentrations of the 5HT2ARAb (10 nM- 1 μM; inhibition of the Q216-N233 amino acid
region of the receptor’s EL2 by 5HT2ARAb) did displace the radiolabeled 5HT2AR
antagonist [3H]ketanserin (2 nM) from its binding sites on human platelets (Fig. 3.6.). This
effect was reversed by preabsorption of 5HT2ARAb with its cognate peptide (Fig. 3.6.).
These data support the notion that 5HT2ARAb’s platelet inhibitory effects involve
interaction with the 5HT2AR ligand binding domain.
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Figure 3.6. 5HT2ARAb displaces the 5HT2AR antagonist from its binding sites.
Binding displacement of the radiolabeled 5HT2AR antagonist [3H]ketanserin (2 nM) with
increasing concentrations of 5HT2ARAb (10 nM-1 μM) in human platelets; preabsorption
of 5HT2ARAb with its cognate peptide (i.e., Q216-N233) reversed its ability to displace
binding of [3H]ketanserin from the 5HT2AR.
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Section 3.5. Discussion
According to the National Blood Clot Alliance, it is estimated that 274 people die every
day from blood clots. This means one person dies every six minutes due to a blood clot
(130-135). While the current FDA approved antiplatelet drugs reduce the risk of recurrent
heart attacks, stroke, and death, they are associated with serious side effects (e.g.,
bleeding) which may outweigh their benefits (136-141). Thus, given the limitations of
current thromboembolic therapy (e.g., resistance, and bleeding associated with plavix®
and/or aspirin), developing safer drugs continues to be a sought after goal.
It has been demonstrated that serotonin/5HT amplifies aggregation triggered by separate
agonists, thereby enhancing thrombogenesis (142, 143). This notion is supported by
clinical data demonstrating that increased blood serotonin levels (144) and hyperactive
5-HT2ARs (144) correlate with cardiac events. Thus, efforts were undertaken to explore
the potential beneficial effects of 5HT2AR antagonists as therapy in patients with
cardiovascular disease. Unfortunately, while the serotonin 5HT2A receptor (5HT2AR) is
known to play a critical role in platelet function in vivo, and has been implicated in several
forms of cardiovascular disorders, currently there are no FDA-approved 5HT2AR
antagonists available for managing thrombotic disease. Nonetheless, a host of such
antagonists were designed and examined throughout the years (53-55, 121, 122). For
example, the 5HT2AR antagonist ketanserin was shown in clinical studies (121) to reduce
the incidence of myocardial infarctions in patients with coronary artery stenosis. However,
these results were accompanied by deleterious side-effects due to lack of selectivity for
5HT2AR (121). Subsequent attempts to design antagonists with improved selectivity
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profiles produced sarpogrelate, which (initially) showed promise in human clinical studies
(122, 145). Unfortunately, this drug did not receive approval by the FDA due to limitations
that are likely associated with its activity on 5HT2BR. Later, an experimental 5HT2AR
antagonist, namely AR246686 was synthesized and tested for its selectivity and efficacy
(55). While AR246686 lacked affinity toward 5HT2BR and 5HT2cR, and exhibited
antithrombotic effects in vitro and in vivo, toxicity has prevented its clinical utility. It is to
be noted that the empirical design of these agents and the lack of understanding the
5HT2AR binding domains likely contributed to this failure. Consequently, it has been
shown that 5HT2AR ligand binding domain resides in the second extracellular loop (EL2;
P209-N233) (124-126) which contains amino acid coordination (124, 125, 146-148) sites
(S219, L229, A230, and N233), which are either shared or unshared between a number of
ligands.
In our efforts to develop a 5HT2AR antagonist, we custom made and characterized an
antibody that targets its ligand binding pocket, i.e., the second extracellular loop Q216-N233
sequence (designated 5HT2ARAb) for its function-blocking activity, in platelets. We
demonstrated that this antibody has antiplatelet activities in both human and murine
platelet models. Thus, we showed that the 5HT2ARAb inhibited serotonin-enhanced
agonist-induced platelet aggregation, whereas it exerted no effects on agonist(alone)induced aggregation, not only in vitro but also ex vivo (under multi-dosing conditions).
Moreover, the 5HT2ARAb was also found to inhibit the ability of serotonin to enhance
agonist-induced secretion, GPIIb/IIIa Activation and PS exposure. Furthermore, we found
that the 5HT2ARAb not only protected against thrombosis but that it did so without
interfering with physiological hemostasis, in mice. Supportingly, it has been previously
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indicated that targeting 5HT2AR allows for the separation of anti-thrombotic activity and
bleeding (53-55). Aside from findings that 5HT alone does not stimulate procoagulant
responses (149), a likely explanation derives from the belief that the 5HT2AR mediated
responses are more involved in the secondary amplification of platelet aggregation in the
growing thrombus, rather than playing a primary role in formation and stabilization of a
hemostatic thrombus, like ADP and thromboxane A2. Another explanation is that the
antibody cannot penetrate the endothelial cell layer, and hence will not reach the smooth
muscle cells; thereby this approach allows for the selective modulation of the platelet
5HT2AR, but not those of the smooth muscle, which are known to affect bleeding time.
Together, these data support the notion that the 5HT2ARAb would be superior to classical
antagonists because its effects will be limited to the platelet 5HT2ARs. It is noteworthy that
an antibody against the GPIIb/IIIa, known as abciximab/ReoPro ®, has previously been
approved by the FDA for antithrombotic purposes. It is possible therefore that 5HT2ARAb
would also have clinical use. Notably, radioligand binding studies revealed that the
aforementioned 5HT2ARAb inhibitory effects derive from its ability to interact with the
5HT2AR protein.
Section 3.6. Conclusion
In conclusion, our study constitutes the first investigation of function blocking antibody
against 5HT2A receptor function. Moreover, it provides novel information concerning a
potential target site, i.e. EL2, for therapeutic intervention. Specifically, 5HT2ARAb
produces significant effects on platelet function and protects against thrombosis with no
effect on bleeding. Collectively, these data suggest that targeting EL2 of 5HT2AR- for
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which currently there are no interventions available for clinical use, may define a new
class of anti-platelet drugs. Thus, future efforts will focus on generating a monoclonal
version of the 5HT2ARAb, and a pharmaceutical formulation for clinical testing.
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